市场调查报告书
商品编码
1468398
2024-2032年按药物类型(化疗、生物疗法、荷尔蒙疗法等)、配销通路(医院药房、药房和零售药房、线上药房)和地区分類的前列腺癌治疗市场报告Prostate Cancer Treatment Market Report by Drug Type (Chemotherapy, Biological Therapy, Hormone Therapy, and Others), Distribution Channel (Hospitals Pharmacies, Drug Stores and Retail Pharmacies, Online Pharmacies), and Region 2024-2032 |
IMARC Group年,全球前列腺癌治疗市场规模达77亿美元。
前列腺癌是一种严重的恶性肿瘤,是由男性前列腺内的各种异常细胞无法控制的分裂和扩张引起的。它可以透过使用各种疗法来治疗,例如疫苗、药物和治疗。其中,化疗、免疫疗法、冷冻疗法、手术、荷尔蒙疗法、标靶疗法和放射疗法是一些最常见的治疗类型,有助于减轻癌细胞在体内的扩散。这些治疗是根据各种评估提供给患者的,例如患者的年龄、所经历症状的严重程度、医疗状况和既往健康史。
摄护腺癌的盛行率不断上升,特别是在不断增加的老年人口中,是目前推动市场成长的主要因素之一。与此一致的是,有利的医疗报销政策的可用性以及一些国家的政府机构为引入患者援助计划(PAP)而采取的众多倡议正在成为其他增长诱导因素。 PAP 是一项有组织的计划,由製药公司控制,透过提供免费治疗药物来向患者提供经济援助。此外,重大技术进步,例如将多参数磁振造影(mp-MRI)设备与非转移性去势抗性(nmCRPC)和转移性荷尔蒙天然(mHNPC)设定相结合,用于早期检测前列腺癌,同时减轻诊断错误,也促进了市场的成长。此外,为引进新型治疗产品而对研发(R&D)活动进行的广泛投资,以及这些产品在各种线上和线下分销渠道上的便捷获取,正在为市场创造积极的前景。
The global prostate cancer treatment market size reached US$ 7.7 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 12.1 Billion by 2032, exhibiting a growth rate (CAGR) of 5.1% during 2024-2032.
Prostate cancer is a type of severe malignant tumor, which is caused by the uncontrollable division and expansion of various abnormal cells in the prostate gland present in men. It can be treated through the use of various therapeutics, such as vaccines, medications, and treatments. Amongst these, chemotherapy, immunotherapy, cryotherapy, surgery, hormonal, targeted and radiation therapy are some of the most common treatment types that aid in mitigating the spread of cancer cells in the body. These therapies are provided to the patient based on various assessments, such as the age of the patient, severity of the symptoms experienced, medical condition, and previous health history.
The increasing prevalence of prostate cancer, especially amongst the rising geriatric population, is one of the prime factors currently driving the market toward growth. In line with this, the availability of favorable medical reimbursement policies and the numerous initiatives being undertaken by the government bodies of several countries for introducing patient assistance programs (PAPs) are acting as other growth-inducing factors. PAP is an organized program, which is controlled by pharmaceutical companies for providing financial assistance to patients by offering free medications for treatment purposes. Moreover, significant technological advancements, such as the integration of multiparametric-magnetic resonance imaging (mp-MRI) devices with non-metastatic castration-resistant (nmCRPC) and metastatic hormone nave (mHNPC) settings for detecting prostate cancer at early stages, while mitigating diagnostic errors, is also contributing to the market growth. Additionally, extensive investments in the research and development (R&D) activities to introduce novel therapeutic products, along with their easy availability across various online and offline distribution channels, are creating a positive outlook for the market.
IMARC Group provides an analysis of the key trends in each sub-segment of the global prostate cancer treatment market report, along with forecasts at the global, regional and country level from 2024-2032. Our report has categorized the market based on drug type and distribution channel.
Chemotherapy
Biological Therapy
Hormone Therapy
Others
Hospitals Pharmacies
Drug Stores and Retail Pharmacies
Online Pharmacies
North America
United States
Canada
Asia-Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
The competitive landscape of the industry has also been examined along with the profiles of the key players being Astellas Pharma Inc., AstraZeneca plc, Bayer Aktiengesellschaft, Dendreon Pharmaceuticals LLC. (Sanpower Group Co. Ltd.), F. Hoffmann-La Roche AG, Ferring B.V., GlaxoSmithKline Plc, Ipsen (Mayroy SA), Novartis International AG, Takeda Pharmaceutical Company Ltd. and Tolmar Pharmaceuticals Inc.